Prolactin receptor antagonist - Bayer HealthCare
Latest Information Update: 22 Oct 2015
At a glance
- Originator Bayer HealthCare
- Mechanism of Action Prolactin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Endometriosis
Most Recent Events
- 22 Oct 2015 Phase-I development for Endometriosis is ongoing in Germany
- 30 Sep 2014 Phase-I clinical trials in Endometriosis in Germany (unspecified route)